Breast cancer development risk: a novel signature based on EV-miRNAs from the EsomirR Study

20250 citationsJournal Articlediamond Open Access

Authors

Bárbara Cardinali · Ospedale Policlinico San Martino

Alice Stella · Ospedale Policlinico San Martino

Simona Coco · Ospedale Policlinico San Martino

Silvia Marconi · Ospedale Policlinico San Martino

Andrea Sciutto · Ospedale Policlinico San Martino

Linda Zinoli · Ospedale Policlinico San Martino

Francesco Boccardo

Abstract

Conclusion:In this large commercial breast cancer cohort, ESR1 variants were detected in 10.7% of patients, frequently at very low VAFs.Paired analysis of Northstar Select with Northstar Response enabled dynamic assessment of emergent and cleared ESR1 variants, supporting the clinical utility of combining both assays to guide therapy planning and disease monitoring in advanced breast cancer.

Topics & Keywords

MicroRNA in disease regulation Biomarkers in Disease Mechanisms Ferroptosis and cancer prognosis

Publication Details

Published in: The Journal of Liquid Biopsy

Volume 9, pp. 100395-100395

DOI: 10.1016/j.jlb.2025.100395

Field-Weighted Citation Impact: 0.00

Command Palette

Breast cancer development risk: a novel signature based on EV-miRNAs from the EsomirR Study

Authors

Abstract

Topics & Keywords

Publication Details